Tangji Medical completed nearly 100 million yuan in Series B financing

Visit the original URL

Recently, 36氪 was informed that Hangzhou Tangji Medical Technology Co., Ltd. (hereinafter referred to as: Tangji Medical) announced that it has completed the B round of investment of nearly 100 million yuan, jointly invested by Shenzhen Tuojin Venture Capital and Guolian Guokang Fund, Tianchao Capital, Garage Coffee acted as financial advisor in this transaction. This round of financing will be used for the registration clinical trial of Tangji Medical’s innovative medical device “Gastric Bypass Stent System”, as well as the R&D and clinical trial preparations of several new products in the R&D pipeline.

Tangji Medical was established in 2016, focusing on the direction of metabolic diseases, and has successfully developed a number of innovative medical devices for the treatment of obesity, type 2 diabetes, non-alcoholic fatty liver disease and other metabolic diseases. The “Gastric Bypass Stent System” independently developed by the company has entered the national “Special Examination Procedure for Innovative Medical Devices” and has been recognized as a Class III innovative medical device by the State Drug Administration. At present, the critical period of device treatment and removal of the clinical trial has been successfully completed, and it has entered the later follow-up stage.

Metabolic diseases are the main cause of global sub-health status, and there is a huge unmet clinical need for their prevention and treatment. According to the “New England Journal of Medicine” data, there are as many as 2.2 billion overweight people in the world, 700 million obese people, and 3.4 million people die each year from obesity or overweight-related diseases. Obesity has become a major public health problem in China. The incidence and growth rate of overweight and obesity in China ranks first in the world, and it has become the country with the largest number of overweight and obesity in the world. It is estimated that by 2030, Chinese adults will suffer from overweight and obesity. The rate will reach 61%.

At the same time: Type 2 diabetes is the world’s largest chronic disease population, and obesity is also a key causative factor. In 2001, Finer et al. proposed the concept of “Diabesity”, which aims to emphasize the importance of obesity in the occurrence and development of type 2 diabetes, and to update the diabetes prevention and treatment model. In addition, non-alcoholic fatty liver disease and obesity are also Positive correlation, and gradually replaced hepatitis as the main cause of liver cancer; polycystic ovary syndrome (PCOS) is the main factor causing infertility in women, and obesity is also a high-risk factor for PCOS.

Surgical treatment of obesity and metabolic diseases has a history of more than half a century, and it is now recognized that surgery is an effective method for rapid, effective and lasting weight loss and treatment of obesity-related metabolic diseases. In July 2016, the global guidelines issued by the World Organization for Diabetes and the Endocrinology Branch of the Chinese Medical Association and the “Consensus on Multidisciplinary Diagnosis and Treatment of Obesity (2021 Edition)” issued by the Chinese Medical Association Diabetes Branch all listed bariatric surgery as an obese type. Preferred regimen for diabetes and obesity treatment.

However, the irreversible damage that bariatric surgery will cause to the human body and its strict indication requirements make many patients “deterrible”. The majority of people with type 2 diabetes still urgently need safer and more effective treatments to help them get rid of their pain. Tangji Medical’s products take into account the effectiveness of surgery and avoid the risk of invasive surgery, lowering the acceptance threshold for both doctors and patients.

Specifically, Tangji Medical combines the concept of gastric bypass weight loss surgery with the implantation of innovative medical devices in the digestive tract, and has developed a “stomach” with minimally invasive intervention, no damage to human structure, easy operation and better patient experience. Diverter stent system”. If the product is launched, it is expected to become the first new therapy for the treatment of metabolic diseases by endoscopic intervention in China.

It is reported that Tangji Medical has established multiple technology platforms as well as R&D, quality, production and supply chain systems and has passed ISO13485 certification. By the end of 2021, in addition to the flagship product “Gastric Bypass Stent System”, Tangji Medical has nearly 10 research projects, and has applied for more than 50 patents. Many products are undergoing clinical trials at different stages in more than 20 well-known domestic top-three hospitals. .

In terms of team, Zuo Yuxing, the founder of Tangji Medical, has rich experience in clinical medicine and commercial sales in domestic and foreign enterprises; the core members of the company have served as the vice president of the Greater China region of a well-known multinational medical device company, the person in charge of market sales or the human resources of well-known domestic enterprises. Resource executive, chief technology officer, clinical registrar, etc.

Recommended reading:

1. Focusing on minimally invasive intervention, Weimai Medical has launched a whole-process management plan for intervention that integrates “eyes, hands and brains”.

2. 36氪 First Release | Focusing on the research and development of high-value consumables and endoscopes for minimally invasive interventional surgery, “Innovi” received a new round of financing of tens of millions of yuan

media coverage

36Kr Investment Community Yiou Entrepreneurship State
Related events

This article is reprinted from: https://readhub.cn/topic/8gSXUuNHwJm
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.